Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 797 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Celgene Clear all
Completed Phase 1 Interventional

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

NCT01545947
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions
CC-223, erlotinib, CC-223, oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

NCT01350947
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia
Interventions
5-Azacitidine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Buffalo, New York • Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 14, 2026, 6:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

NCT01938833
View directory record Official record
Conditions
HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Romidepsin, Abraxane
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 14, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Lenalidomide and Paclitaxel in Prostate Cancer

NCT00933426
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lenalidomide, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

NCT01177735
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 14, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional Results available

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT01401322
View directory record Official record
Conditions
Leukemia, Relapsed Adult Acute Lymphocytic Leukemia
Interventions
Lenalidomide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01155362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional Results available

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

NCT01241786
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma
Interventions
Revlimid, Azacitidine
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

NCT00073723
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

NCT01827111
View directory record Official record
Conditions
Melanoma
Interventions
ABI-007, Ipilimumab, Phone Call
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00096044
View directory record Official record
Conditions
Leukemia
Interventions
rituximab, lenalidomide
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

NCT00660400
View directory record Official record
Conditions
Leukemia
Interventions
5-azacitidine, Allogeneic Hematopoietic Cell Transplantation (HCT)
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 68 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

NCT00540579
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pomalidomide, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Results available

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

NCT01324323
View directory record Official record
Conditions
Hematologic Malignancy, Malignant Lymphoma
Interventions
Romidepsin, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 14, 2026, 6:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

NCT03030261
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Elotuzumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Denver, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Completed No phase listed Observational

Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer

NCT01096394
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 14, 2026, 6:41 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access for CC-2001

NCT03723083
View directory record Official record
Conditions
Dermatologic, Other
Interventions
CC-2001
Drug
Lead sponsor
Celgene
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

NCT00737529
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
31
States / cities
Little Rock, Arkansas • La Jolla, California • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 14, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

NCT00860457
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Rituximab, Fludarabine, Lenalidomide
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 14, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

NCT00407407
View directory record Official record
Conditions
Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
Interventions
ABI-007, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma

NCT01537744
View directory record Official record
Conditions
Solid Tumors, Virally Mediated Cancers and Liposarcoma
Interventions
oral 5-azacitidine in combination with romidepsin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 14, 2026, 6:41 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Romidepsin and Bortezomib for Multiple Myeloma

NCT00765102
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Romidepsin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Loma Linda, California • Rancho Mirage, California • Santa Barbara, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 14, 2026, 6:41 PM EDT